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Vesicoureteral reflux and antibiotic prophylaxis: why cohorts 
and methodologies matter
Saul P. Greenfield, MD, Earl Cheng, MD, William DeFoor, MD, Bradley Kropp, MD, H. Gil 
Rushton, MD, Steve Skoog, MD, and Myra Carpenter, PhD
Abstract
Purpose—Published cohorts of children with vesicoureteral reflux placed on antibiotic 
prophylaxis differ in baseline characteristics and methodology. These data have been combined in 
meta-analyses to derive treatment recommendations. We analyzed these cohorts in an attempt to 
understand the disparate outcomes reported.
Materials and Methods—Eighteen studies were identified from 1987 to 2013. These either 
retrospectively or prospectively evaluated children with VUR who were on long-term antibiotic 
prophylaxis. The presenting demographic data, criteria and methods of evaluation were tabulated. 
Outcomes were compared—specifically recurrent urinary infection and renal scarring.
Results—Significant differences in baseline characteristics and methodology were identified: 
gender, circumcision status, grade of reflux, evaluation of bowel and bladder dysfunction (BBD), 
methodology of urine collection, definition of urinary infection (UTI), measurement of 
compliance, means of identifying renal scarring. Cohorts with larger numbers of uncircumcised 
boys had more breakthrough UTI’s. Both infection and renal scarring rates were higher in series 
with higher grades of reflux. Bagged urine specimens were allowed in 6 series, rendering the data 
suspect. Children with BBD were excluded from 3 cohorts; only in 1 was BBD correlated with 
outcome. Compliance was monitored in only 6 studies.
Conclusions—Sub-populations as well as methodologies vary significantly in published series 
of children with VUR on anti-biotic prophylaxis. It is inappropriate to combine outcome data from 
these series in a meta-analysis, since this serves to blur distinctions between these sub-populations. 
Broad recommendations or guidelines based upon meta-analyses should be viewed with caution.
Introduction
The diagnosis and treatment of vesicoureteral reflux (VUR) in children remains an unsettled 
issue, despite numerous prospective and retrospective studies. Vesicoureteral reflux can be 
associated with recurrent urinary infection, pyelonephritis and renal scarring. Long term 
antibiotic prophylaxis has been the mainstay of treatment, based upon studies comparing 
prophylaxis with anti-reflux surgery. A majority of children with reflux--primarily with 
lower grades I, II & III—will outgrow the condition and appear at less risk for recurrent 
infection and renal involvement. Identification of those most at risk remains a challenge and 
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no clear methodology exists to definitively segregate those who do not require either medical 
or surgical intervention. Most recently, meta-analyses which include series comparing long 
term prophylaxis to no treatment have led to recommendations and guidelines against 
evaluation of all infants and children after a first urinary infection and against antibiotic 
prophylaxis for all children discovered to have VUR. [1, 2] Meta-analyses which include the 
Randomized Intervention for Children with Vesicoureteral Reflux (RIVUR) trial come to the 
opposite conclusion. [3] It may be inappropriate, however, to combine data from disparate 
studies, since the populations in each cohort differ.
We evaluated series that span 3 decades and represent investigations of diverse populations 
internationally, evaluating the outcomes of children with VUR on long term antibiotic 
prophylaxis. The study populations differ from one another in many crucial demographic 
aspects: age of presentation, grade of VUR, gender distribution, circumcision status. 
Furthermore, these studies also differ in methodology: definition of urinary infection, 
standardization of radiographic interpretation, radiographic evaluation of renal scarring, 
assessment of bowel and bladder dysfunction and compliance with taking medicine. It is 
possible that the conflicting and muddled conclusions of these studies are due to the 
underlying differences in study populations and methodology. We examined 18 studies 
which evaluated the outcome of children on long-term antibiotic prophylaxis, in an attempt 
to understand the differing outcomes. This is not intended to be a meta-analysis, as the data 
from these studies is not combined, but rather examined separately.
Materials and Methods
A literature search was performed using the Ovid MEDLINE data base. Eighteen studies 
were identified from 1974 to 2013. [4–25] These all either retrospectively or prospectively 
evaluated children with VUR and included a cohort who were on long-term antibiotic 
prophylaxis. No studies were excluded. The presenting demographic data, criteria and 
methods of evaluation were tabulated. Outcomes were compared—specifically recurrent 
urinary infection and renal scarring—when the data allowed.
Results
Presenting Demographics
The presenting demographics are shown in Table 1: Nine studies were from Europe; 4 from 
North America; 1 from Europe and North America; 1 from South America and North 
America; 1 from South America; 1 from Australia; 1 from Japan. Greenfield [15] and Skoog 
[4] were retrospective studes, while the remainder were prospective. The gender distribution 
differed widely. The percentage of boys varied from none to 79%. Studies from Europe, 
Asia and Australia had a greater percentage of boys. Studies from North America were 
predominately female—72 to 100%. [4, 5, 9, 15] Males were overwhelmingly dominant 
(80%) in the one study from Japan. [6] Males comprised 30 to 50% of the cohort in 8 studies
—all from countries were routine neonatal circumcision is not practiced. 
[8,13,14,16,17,18,19,23,24] In the four studies wherein circumcision status was provided, 
the vast majority were not circumcised—63 to 97%. [9,10,13,14,17] Notably, in the US 
RIVUR study, among the small number of male patients, 63% were not circumcised. [9] 
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While not indicated in the manuscripts, it can be assumed that the majority of boys from 
countries were neonatal circumcision is not routinely practiced were not circumcised. The 
age distribution varied widely, mainly in limiting the upper age included. Four studies 
included children only up to age 3 years; 1 included children up to age 6 years; 12 included 
children as old as 18 years.
Presenting Clinical Characteristics
The presenting VUR grades are shown in Table 2. The older studies did not use the 
International Scale (IS). VUR was described as dilating or non-dilating or graded on a scale 
of I, II or III. Dilating VUR was considered grade III or above for the purpose of this 
analysis. In the 3 point system grade I is equal to grade I (IS); grade II is equal to grades 
II,III (IS); and grade III is equal to grades IV, V (IS). 3 studies included children with grades 
III (IS) or less; 8 studies included children with grades IV or less and 6 included grade V or 
less. Five studies either completely excluded grades I and II or were predominantly—greater 
than 75%--grades III to IV VUR.
Febrile urinary tract infection was the sole reason for presentation in 4 series (Table 3). 
Febrile, non-febrile, non-specified or symptomatic UTI was the reason for presentation in 
the remainder. Two studies also included children who presented without UTI, but with 
voiding dysfunction or prenatally detected hydronephrosis. [13, 14, 15] Minimum colony 
counts were required for inclusion in 7 series, while in the remaining 11 no colony counts 
were mentioned. A urinalysis with pyuria was required in 6 studies, while no mention of 
urinalysis results was made in the remaining 12 studies. The means of specimen collection 
was not specified in 9; by collection bag in infants in 6; by catheter only in infants in 3. 
Bowel and bladder function (BBD) was assessed in toilet trained children in 5 studies and in 
2 of those children with BBD were excluded from analysis. In 13 studies BBD was not 
assessed.
Presenting Radiographic Upper Tract Findings
Presenting radiographic modalities and findings are shown in Table 4. Children in 11 studies 
underwent radionuclide scanning (RS) at the outset; five had intravenous pyelograms (IVP), 
1 had a renal ultrasound and in 1 no initial assessment of parenchymal status was performed. 
Of those in whom initial renal scarring was assessed, the incidence of scarring in the cohort 
was < 10% in 4 studies, 10 to 25% in 1, 25 to 40% in 1 and >40% in 8. Renal ultrasound 
was performed adjunctively in 4 studies—3 also had a renal scan and 1 had an IVP.
Clinical Protocols
Salient details of the clinical protocols are shown in Table 5. Follow up was 2 years or less 
in 8 studies, 5 years in 4, greater than 5 in 4 and not specified in 2. The prophylactic 
medication was not specified in 7, TMP/SMZ or Nitrofurantoin in 5, TMP/SMZ in 3, 
Nitrofurantoin in 1, Cefaclor in 1, Trimethoprim or Augmentin in 1. Attempts to measure 
compliance with medicine taking were made in 6 studies, while in 12 no method to assess 
compliance was reported.
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The major outcomes tabulated while on antibiotic prophylaxis were recurrent UTI, renal 
scarring and resolution of reflux. These are shown in Table 6. Recurrent UTI while on 
prophylaxis was not stated in 3 studies and overall ranged from 7 to 50%. When specified, 
the majority were febrile. The gender of those with recurrent UTI was specified in 3 studies. 
[6, 9, 13, 14] In 2 the majority were female, 80% and 93%, respectively. [9, 13, 14] In the 
one study from Japan wherein the 79% of the subjects were male, 91% of recurrent 
infections were in boys. [6] Scarring at the end of the study was not specified in 5 studies. 
Radionuclide renal scans were performed 8 studies and scarring ranged from .5 to 17%. 
IVP’s were used to assess scarring in 4 older studies and rates were higher—ranging from 
4.5 to35%. Resolution of reflux at the end of the study period was not specified in 8 series. 
The rate of reflux resolution of specific grades was shown 3 studies and ranged widely from 
10 to 94%. Overall resolution rates were provided in 7 studies, without specifying grade, and 
they ranged from 13 to 51%.
Discussion
This detailed examination of the populations in these studies demonstrates that there are 
relevant differences, which may account for disparate outcomes. Studies with patients from 
the United States or in whom patients from the United States were included tended to have a 
majority of girls—ranging from approximately 80 to 100%. Conversely, studies from 
Europe, Japan and Australia had much higher percentages of boys—ranging from around 40 
to 80%. While it is impossible to be certain, this may account for the relatively high 
recurrent UTI rate in these studies, since routine neonatal circumcision is not practiced in 
those countries and boys with intact foreskins and VUR are at a higher risk of urinary 
infection. [26] Unfortunately, the gender of those with recurrent UTI was not always 
revealed. However, the few males in the RIVUR study who had UTI’s on medication were 
all uncircumcised. 91% of the recurrent UTI’s in the Kaneko series from Japan were in boys 
and, again, routine neonatal circumcision is not practiced in Japan. An exception was the 
earlier experience of Govan, wherein all the subjects were female and a large percentage 
(50%) developed infection on prophylaxis. [5] Looking at all the rates of recurrent UTI and 
gender, it is a mixed picture, but gender and circumcision status may play a significant role 
in presentation and in overall success of long term prophylaxis. This remains a speculation, 
however, until and unless proven by properly performed trials with well identified subgroups 
of circumcised and uncircumcised boys.
By design, the grades included in these studies varied widely. The IRSC and Swedish trials 
limited themselves to higher grade (III, IV) VUR at the outset. The Birmingham and Smellie 
series also had a majority with “dilating” VUR. For the remainder, most of the reflux ranged 
from grades I to III. The highest outcome scarring rates, determined either by renal scan or 
IVP, were in those studies with higher grades—ranging from 13 to 35%. [16, 23, 24] Lower 
outcome scarring rates were seen in studies predominated by the lower grades—ranging 
from 3.5 to 12%. [9, 12, 18] Ages included varied widely, and many studies included 
children older than 10 years. Given the differing genders and VUR grades included, there 
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were no clear outcome discrepancies when comparing studies that were confined to younger 
children to those with older children.
The definition of UTI, either at entry or during the period of observation also varied 
significantly. Two studies included children without a history of infection, but who presented 
with hydronephrosis or voiding dysfunction. [13, 14, 15] The majority of the infections at 
presentation and follow up were febrile. Minimal colony counts were not specified in seven 
series. In eleven, urinalysis results were not reported and the presence of pyuria was not 
required in order to diagnose UTI. The method of urine collection was not specified in 9 
series. In 3 studies, only catheterized specimens were allowed from non-toilet trained infants 
and recurrent UTI rates ranged from 9 to 20%. [7, 9, 17] Bagged specimens from non-toilet 
trained infants were permitted in 6 series and recurrent UTI’s ranged from 7 to 36%. [8, 13, 
14, 18, 19, 24, 25] The inclusion of bagged specimens renders the data suspect, since such 
specimens can be contaminated—falsely increasing the reported infection incidence. Again, 
VUR grade and gender distribution varied, perhaps also accounting for some differences in 
UTI occurrence while on medication.
Renal scarring at presentation was not specified in 3 series. [6, 7, 8] IVP’s were the 
radiographic tool used to assess scarring in 4 older studies, while the remaining 11 studies 
employed radionuclide scanning. 4 studies had initial scarring rates 10% or less, while in the 
remainder initial scarring rates ranged from 25 to 100%. Of those 4 with the lowest initial 
scar rates, reported outcome scarring ranged from 0.5 to 35% and reported recurrent UTI 
rates were 13%. [4, 9, 15, 16] The remainder with higher initial scarring rates reported 
recurrent UTI rates ranging from 14 to 50% and scarring at outcome ranging from 3.5 to 
35%.
Bowel and bladder dysfunction (BBD) was not noted in the majority. In 3 series it was 
assessed and children with BBD were excluded. [10, 12, 20, 21, 22] In 2 series BBD was 
prospectively assessed in the studied cohort and only in the RIVUR study was BBD 
correlated with outcome. [9] Subjects in the RIVUR trial with BBD had a much higher 
incidence of infection while on prophylaxis. The purposeful exclusion of children with BBD 
or the failure to assess for BBD, therefore, might significantly alter the outcome of long term 
prophylaxis in a cohort of children with VUR. In six series, attempts at compliance 
enforcement and monitoring occurred. In particular, the Roussey-Kesler series, wherein 
compliance was not monitored, reported that 25% of children on TMP/SMZ had infections 
sensitive to the antibiotic, suggesting that the subjects were not taking the medication. [8] 
The efficacy of prophylaxis might not be accurately evaluated, therefore, unless some effort 
at compliance is present. Follow up ranged from 1 to 5 years. No correlation between 
outcomes and follow up length was evident.
Conclusion
This review demonstrates that the sub-populations of children with VUR have differed in 
previously published studies of antibiotic prophylaxis and VUR. In addition, the definition 
of UTI and means of assessing renal involvement was also variable. Their reported clinical 
outcomes differ as a result. It may, therefore, be inappropriate to combine outcome data 
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from these series in a meta-analysis, since this serves to blur distinctions between these sub-
populations. The results of such a meta-analysis will not help the clinician to properly 
customize treatment or to understand the benefits and limitations of long term antibiotic 
prophylaxis in a given individual. Unfortunately, there are no clear recommendations when 
looking at these studies one at a time either, since within each study sub-populations are 
combined. It is probable that expectations for the efficacy of antibiotic prophylaxis for an 
uncircumcised male infant with grade IV VUR will not be the same as for a 5 year old girl 
with BBD and grade II VUR. Subpopulations, categorized by grade, gender, age, 
circumcision status and toilet habits, would have to be observed individually while on and 
off prophylaxis. Given that prospective studies that are randomized, controlled, blinded and 
with statistical significance for each subpopulation may not be forthcoming, the clinician is 
left with the need to make individual judgments and follow these children carefully. Explicit 
guidance from the literature is not available for each sub-group or clinical scenario. Broad 
recommendations or guidelines based upon meta-analyses, therefore, should be viewed with 
caution.
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Table 4
Presenting Upper Tract Radiographic Findings
RS/IVP Renal USG % Renal Scar
RIVUR
9 RS yes 4
SRT
13, 14 RS no 62
Craig
17 RS yes 25
Pennesi
18 RS no 40
Montini
19 RS no 94
Roussey-Kesler
8 none yes ns
Garin
7 RS yes ns
Kaneko
6 none no ns
Smellie
23 RS no 100
IRSC (EUR)
20, 21, 22 RS yes 82
Greenfield
15 RS no 10
Scholtmeijer
16 RS/IVP no 6
IRSC (EUR/US)
10 IVP no 66
Goldraich
12 RS no 44
Skoog
4 RS no 8.2 %
Birm: 2 yrs
24 IVP no 59
Birm: 5 yrs
25 IVP no 59
Govan
5 IVP no 56
(RS: radionuclide renal scan, IVP: intravenous pyelogram, USG: renal ultrasound, SRT: Swedish Reflux Trial, IRSC: International Reflux Study in 
Children, Birm: Birmingham Reflux Study)













Greenfield et al. Page 12
Table 5
Clinical Protocol
Follow up Medication Compliance Measured
RIVUR
9 2 yr TMP/SMZ yes
SRT
13, 14 2 yr TMP,cefadox, nitro yes
Craig
17 12 mo ns yes
Pennesi
18 2 yr TMP/SMZ no
Montini
19 12 mo co-TMP, Amox/Clav yes
Roussey-Kesler
8 18 mo TMP/SMZ no
Garin
7 1 yr TMP/SMZ, Nitro yes
Kaneko
6 16 mo cefaclor no
Smellie




20, 21, 22 5 yr ns no
Greenfield
15 ns TMP/SMZ, nitro no
Scholtmeijer
16 ns ns no
IRSC (EUR/US)
10 5 yr ns no
Goldraich
12 69 mo Nitro yes
Skoog
4 5 yr ns no
Birm: 2 yrs
24 2 yr TMP/SMZ, nitro no
Birm: 5 yrs
25 5 yr TMP/SMZ, nitro no
Govan
5 1–6 yr ns no
(TMP: trimethoprim, TMP/SMZ: trimethoprim sulfamethoxazole, Nitro: nitrofurantoin, Amox/Clav: amoxicillin/clavulinic acid, SRT: Swedish 
Reflux Trial, IRSC: International Reflux Study in Children, Birm: Birmingham Reflux Study)













Greenfield et al. Page 13
Table 6
Clinical Outcomes
UTI %Scar (RS) %Scar (IVP) VUR res olution
RIVUR
9 13%, 3/4f 12% ns 51%
93% female, 7% male (all uncirc)
SRT
13, 14 14% all f 0% ns 13%
80% female
Craig
17 9% all f 8% ns ns
Pennesi
18 36% 10% ns I:96%,II:86%,III:74%,IV:94%
Montini
19 7% all f ns 1% ns
Roussey-Kesler
8 17% 3/4f ns ns ns
Garin
7 20% 6% ns I: 37.5%,II:12.5%,III: 10.3%
Kaneko
6 28%
91% male ns ns ns
Smellie
23 32% 13% ns 20%
IRSC (EUR)
20, 21, 22 28%, 57%f 17% ns ns
Greenfield
15 13% ns ns 29%
Scholtmeijer
16 ns ns 3% ns
IRSC (EUR/US)
10 ns ns 20% ns
Goldraich
12 43.5% 3.5% ns 40%–90% (low gr-high gr)
Skoog
4 ns .5% ns 41%
Birm: 2 yrs
24 23% ns 35% 43%
Birm: 5 yrs
25 21% ns 4.5% 49%
Govan
5 50% 3/4f ns ns ns
(UTI/f: febrile, ns: not shown, SRT: Swedish Reflux Trial, IRSC: International Reflux Study in Children, Birm: Birmingham Reflux Study)
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